M.C.Jayasingh v. Mishra Dhatu Nigam Limited (MIDHANI)

168821

The appellant, M.C. Jayasingh, filed suit seeking perpetual injunction against respondents for infringing his patents related to Custom Mega Prosthesis used in limb salvage surgery. He had previously sought an interim injunction which was rejected by the single judge. The appeal challenged this rejection.

Jurisdiction
India
Court
Madras High Court
Case Number
168821
Judge(s)
S.J.Mukhopadhaya,V.Dhanapalan

Detailed Summary

In the high-stakes world of medical innovation, timing is everything. A patent can be your strongest shield, but only if a court believes you need urgent protection. When M.C. Jayasingh, the holder of patents for a Custom Mega Prosthesis used in limb salvage surgery, watched a public sector competitor allegedly step into his territory, he turned to the courts for an emergency injunction. What followed was a sobering lesson on why interim relief is not handed out lightly—and why inventors must come prepared with more than just a valid patent.

M.C. Jayasingh, the appellant, held patents related to a Custom Mega Prosthesis—a specialized medical device used in limb salvage surgery, a procedure that can mean the difference between amputation and recovery for patients facing severe bone or joint damage. The respondent, Mishra Dhatu Nigam Limited (Midhani), is a public sector undertaking. Jayasingh filed a suit seeking a perpetual injunction, alleging that Midhani was infringing his patented technology. Before the full trial could unfold, Jayasingh sought an interim injunction—an urgent court order to stop the alleged infringement while the case was still being decided. A single judge reviewed his request and rejected it. Jayasingh then appealed that rejection, bringing the matter before the appellate court on 29 April 2009.

Jayasingh's argument centered on the value of his patented innovation and the harm he stood to suffer if Midhani continued its allegedly infringing activities during the pendency of the suit. As the holder of patents for a device with life-changing medical applications, he contended that the court should step in immediately to preserve his rights. On the other side, the respondent presented a case that was sufficient to convince the single judge—and later the appellate court—that an interim injunction was not warranted. The legal friction here was classic: an inventor claiming urgent harm versus a respondent whose product similarities were not immediately apparent, and whose operations carried public sector weight. The court had to weigh whether Jayasingh had demonstrated the kind of irreparable injury and balance of convenience that would justify halting the respondent's activities before the full trial.

The appellate court upheld the rejection of the interim injunction. The outcome was defendant-favorable, meaning Midhani was not required to halt its operations during the pendency of the suit. The decision underscored a fundamental principle of patent litigation: interim injunctions are extraordinary remedies, not automatic entitlements. Even when a patent holder has a legitimate grievance, the court must be convinced that waiting for a full trial would cause harm that cannot be undone, and that the inconvenience to the party being restrained outweighs the harm to the patent holder. Without a clear demonstration of irreparable injury and a convincing balance of convenience, the court will not pull the emergency brake.

For founders, inventors, and IP professionals, this case is a stark reminder: holding a patent is not the same as securing immediate protection. If you believe your patent is being infringed, do not assume that a court will grant an emergency injunction simply because your patent is valid. You must build a compelling case for irreparable injury—showing that the harm you face cannot be compensated by money or fixed after a full trial. Equally important, you must demonstrate that the balance of convenience tips in your favor. When product similarities are not immediately obvious, or when the alleged infringer is a large or public entity with significant operations, the court will be even more cautious. Prepare your evidence meticulously, document every instance of alleged infringement, and consult experienced IP counsel before seeking interim relief. In patent disputes, the strongest shield is one backed by unshakeable proof.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Madras High Court. Understanding the court's reasoning in M.C.Jayasingh vs Mishra Dhatu Nigam Limited (MIDHANI) is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patent109581781

Pranathmaka Ayurvedics Pvt LtdvsCocosath Health Products

This original petition challenged an interim injunction granted by the Commercial Court, Ernakulam, which restrained Pranathmaka Ayurvedics Pvt Ltd from appointing exclusive global marketers and transferring confidential product know-how. The High Court dismissed the petition, holding that since the petitioners had not shown reason for not availing the statutory remedy of appeal under Section 13(1) of the Commercial Courts Act, 2015, it would not interfere with the lower court's order.

patent1671966

Natco Pharma LimitedvsUnion Of India & Ors.

The Supreme Court addressed an appeal concerning patentability issues involving crystal modification of an N-Phenyl-2-Pyrimidineamine derivative. The core issue was the absence of a qualified Technical Member in the Intellectual Property Appellant Board (IPAB).

patent41058758

PrasadvsThe Controller Of Patents and Design, Kolkata and Anr

The case was transferred from the Intellectual Property Appellate Board (IPAB) to the Calcutta High Court following the enactment of the Tribunals Reform Act, 2021. The court directed its Commercial Appellate Division to issue notices and file a report before listing the matter in March 2023.

patent180236786

Novartis AgvsMSN Laboratories Pvt Ltd

The petitioner filed an application alleging that the defendant violated a prior injunction by offering to supply Eltrombopag Olamine to the Government. The court examined whether this offer, made under Section 100 of the Patents Act, 1970, constituted contempt.

patent48846051

Bristol-Myers Squibb Holdings Ireland Unlimited CompanyvsBdr Pharmaceuticals International Pvt. Ltd.

The plaintiffs sought a permanent injunction against the defendants for dealing in generic APIXABAN infringing Indian Patent No. IN'247381. The dispute centered on whether the defendants' continued activities, such as participating in tenders and authorizing distributors post-injunction, constituted willful disobedience or contempt of court.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call